174 related articles for article (PubMed ID: 27096597)
1. Ibrutinib for Chronic Lymphocytic Leukemia.
Ruchlemer R; Ben Ami R; Lachish T
N Engl J Med; 2016 Apr; 374(16):1593-4. PubMed ID: 27096597
[No Abstract] [Full Text] [Related]
2. Ibrutinib for Chronic Lymphocytic Leukemia.
Rigolin GM; Cavazzini F; Cuneo A
N Engl J Med; 2016 Apr; 374(16):1593. PubMed ID: 27096596
[No Abstract] [Full Text] [Related]
3. Ibrutinib for Chronic Lymphocytic Leukemia.
Sharman JP; Mato AR; Keating MJ
N Engl J Med; 2016 Apr; 374(16):1592-3. PubMed ID: 27096595
[No Abstract] [Full Text] [Related]
4. Ibrutinib for Chronic Lymphocytic Leukemia.
Burger JA; Styles L; Kipps TJ
N Engl J Med; 2016 Apr; 374(16):1594-5. PubMed ID: 27096594
[No Abstract] [Full Text] [Related]
5. Ibrutinib increased survival more than chlorambucil in older patients with untreated chronic lymphocytic leukemia.
Aronson FR
Ann Intern Med; 2016 Apr; 164(8):JC44. PubMed ID: 27089094
[No Abstract] [Full Text] [Related]
6. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Burger JA; Tedeschi A; Barr PM; Robak T; Owen C; Ghia P; Bairey O; Hillmen P; Bartlett NL; Li J; Simpson D; Grosicki S; Devereux S; McCarthy H; Coutre S; Quach H; Gaidano G; Maslyak Z; Stevens DA; Janssens A; Offner F; Mayer J; O'Dwyer M; Hellmann A; Schuh A; Siddiqi T; Polliack A; Tam CS; Suri D; Cheng M; Clow F; Styles L; James DF; Kipps TJ;
N Engl J Med; 2015 Dec; 373(25):2425-37. PubMed ID: 26639149
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Ibrutinib Compared With Obinutuzumab With Chlorambucil in Untreated Chronic Lymphocytic Leukemia Patients With Comorbidities in the United Kingdom.
Sinha R; Redekop WK
Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):e131-e142. PubMed ID: 29398648
[TBL] [Abstract][Full Text] [Related]
8. Survival adjusting for crossover: phase 3 study of ibrutinib
Coutre S; Tedeschi A; Robak T; Barr PM; Owen C; Bairey O; Burger J; Zhou C; Styles L; James DF; Kipps TJ
Haematologica; 2018 Jun; 103(6):e249-e251. PubMed ID: 29170253
[No Abstract] [Full Text] [Related]
9. Ibrutinib in relapsed chronic lymphocytic leukemia.
Neffendorf JE; Gout I; Hildebrand GD
N Engl J Med; 2013 Sep; 369(13):1277. PubMed ID: 24066759
[No Abstract] [Full Text] [Related]
10. Ibrutinib in relapsed chronic lymphocytic leukemia.
Byrd JC; O'Brien S; James DF
N Engl J Med; 2013 Sep; 369(13):1278-9. PubMed ID: 24066758
[No Abstract] [Full Text] [Related]
11. Ibrutinib in relapsed chronic lymphocytic leukemia.
Rushworth SA; MacEwan DJ; Bowles KM
N Engl J Med; 2013 Sep; 369(13):1277-8. PubMed ID: 24066760
[No Abstract] [Full Text] [Related]
12. Life after ibrutinib? A new unmet need in CLL.
Pinilla-Ibarz J; Chavez JC
Blood; 2015 Mar; 125(13):2013-4. PubMed ID: 25814485
[TBL] [Abstract][Full Text] [Related]
13. The emerging role of ibrutinib in the treatment of chronic lymphocytic leukemia.
Molica S
Expert Rev Hematol; 2013 Oct; 6(5):543-6. PubMed ID: 24083545
[TBL] [Abstract][Full Text] [Related]
14. Idelalisib, ibrutinib show benefits in CLL.
Cancer Discov; 2014 Apr; 4(4):382. PubMed ID: 24706642
[No Abstract] [Full Text] [Related]
15. Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study.
Montillo M; O'Brien S; Tedeschi A; Byrd JC; Dearden C; Gill D; Brown JR; Barrientos JC; Mulligan SP; Furman RR; Cymbalista F; Plascencia C; Chang S; Hsu E; James DF; Hillmen P
Blood Cancer J; 2017 Feb; 7(2):e524. PubMed ID: 28157216
[No Abstract] [Full Text] [Related]
16. Ibrutinib for Chronic Lymphocytic Leukemia with
Ahn IE; Tian X; Wiestner A
N Engl J Med; 2020 Jul; 383(5):498-500. PubMed ID: 32726539
[No Abstract] [Full Text] [Related]
17. Refractory pure red cell aplasia associated with chronic lymphocytic leukemia successfully treated with ibrutinib.
Goldschmidt N; Rund D
Leuk Lymphoma; 2017 Feb; 58(2):498-500. PubMed ID: 27756158
[No Abstract] [Full Text] [Related]
18. Remineralization of lytic bone disease in a patient with small lymphocytic lymphoma using ibrutinib.
Tucker DL; Mihailescu L; Riordan R; Rule S
Br J Haematol; 2017 Jul; 178(1):153-155. PubMed ID: 27172457
[No Abstract] [Full Text] [Related]
19. Alliance to iLLUMINATE the chemo-free sign.
Romero D
Nat Rev Clin Oncol; 2019 Feb; 16(2):65. PubMed ID: 30575810
[No Abstract] [Full Text] [Related]
20. FDA grants accelerated approval for ibrutinib for CLL.
Dangi-Garimella S
Am J Manag Care; 2014 Mar; 20(5 Spec No.):E10. PubMed ID: 25618623
[No Abstract] [Full Text] [Related]
[Next] [New Search]
